Immune-targeted mAb from Biocon, Equillium to enter global trials after Indian approval in COVID-19 patients

Biocon’s report of reduced mortality in hospitalized COVID-19 patients treated with Alzumab and its resulting emergency approval in India has prompted Equillium to send the immune modulator into a global testing.

Equillium Inc. (NASDAQ:EQ), which holds exclusive rights in the U.S., Canada, Australia and New Zealand to Alzumab itolizumab, gained $23.31 (731%) to $26.50 on Monday to reach a valuation of $468.6 million. ...